18 Results for "

extracellular ATP

" in MedChemExpress (MCE) Product Catalog:
Products (18)

18 Results for "extracellular ATP" in MCE Product Catalog:

5
5 Cited Publications
Cat. No.: HY-P2764
CAS No.: 9000-95-7
Target:  

NTPDase

Research Areas:  

Inflammation/Immunology

Apyrase is an Nucleoside triphosphate diphosphohydrolase (NTPDase). Apyrase can hydrolyze extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP). Apyrase can inhibit Stx2 toxin release of enterohemorrhagic Escherichia coli (EHEC) infection and protect the intestinal barrier function. Apyrase can be used for the research of infection and inflammation, such as hemorrhagic colitis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12283
CAS No.: 156722-18-8
Purity:  99.03%
Synonyms: PST 2238
Target:  

Na+/K+ ATPase RSV

Research Areas:  

Cardiovascular Disease

Rostafuroxin (PST 2238), a digitoxigenin derivative, is an orally active and potent Na +,K +-ATPase (ATP1A1) antognist. Rostafuroxin binds specifically to the ATP1A1 extracellular domain and blocks respiratory syncytial virus (RSV)-triggered EGFR Tyr845 phosphorylation. Rostafuroxin has antihypertensive and anti-RSV activity .
loading...
    loading...
Cat. No.: HY-103322
CAS No.: 1135306-29-4
Target:  

PKA Potassium Channel

Research Areas:  

Metabolic Disease Cancer

6-Bnz-cAMP sodium, a derivative of cyclic adenosine monophosphate (cAMP), is a selective PKA activator with inhibitory activity against the bTREK-1 K + channel. 6-Bnz-cAMP sodium does not activate the Epac signaling pathway. It inhibits the bTREK-1 K + channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP sodium activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. It can be used in studies related to bone tissue repair and regeneration .
loading...
    loading...
Cat. No.: HY-124309
CAS No.: 1269802-97-2
Purity:  99.30%
Research Areas:  

Cancer

NHI-2 is a lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 14.7 µM. NHI-2 shows selective for LDHA over LDHB (IC50 = 55.8 µM). NHI-2 is an efficient anti-glycolytic agent. NHI-2 enhances apoptosis, induces cell cycle arrest at S and G2 phases. NHI-2 has a broad spectrum anti-proliferative activity in cancer cells. NHI-2 affects extracellular acidification rate and ATP production. NHI-2 suppresses tumor growth in murine B78 melanoma tumor model .
loading...
    loading...
Cat. No.: HY-34154
CAS No.: 619-60-3
Target:  

Lactate Dehydrogenase

Research Areas:  

Others

4-(Dimethylamino)phenol is a potent cyanide antidote. 4-(Dimethylamino)phenol increases the extracellular lactate dehydrogenase (LDH) without markedly affecting gluconeogenesis. 4-(Dimethylamino)phenol cannot decreases the ATP content until the membrane becomes permeable to LDH. 4-(Dimethylamino)phenol’s toxicity is related to its reaction with glutathione and formation of covalent complexes, leading to impaired cellular function .
loading...
    loading...
Cat. No.: HY-P990068
CAS No.: 2643331-31-9
Synonyms: SRF617

Target:  

NTPDase

Research Areas:  

Inflammation/Immunology Cancer

Perenostobart (SRF617) is a human IgG4 antibody with inhibitory activity against CD39 ATPase. Perenostobart inhibits CD39-mediated hydrolysis of extracellular ATP to AMP, with IC50 values of 1.9 nM (HEK293 OE cells), 0.7 nM (MOLP-8 cells), and 1.2 nM (RBC-lysed whole blood). Perenostobart enhances CD4 + T-cell proliferation, promotes dendritic cell maturation, and boosts inflammasome activation in macrophages in the presence of ATP. Perenostobart demonstrates significant single-agent anti-tumor efficacy in MOLP-8 and H520 xenograft models. Perenostobart can be used for the study of cancer .
loading...
    loading...
Cat. No.: HY-N2452
CAS No.: 956103-79-0
Cochinchinenin C is a GLP-1R agonist that binds to the extracellular domain of the receptor via hydrophobic interactions and hydrogen bonds, and promotes glucose-dependent insulin secretion from pancreatic β-cells. Cochinchinenin C also increases intracellular cAMP and ATP levels. At low concentrations, Cochinchinenin C binds to human serum albumin, alters its microenvironment, and induces dominant static fluorescence quenching. Cochinchinenin C shows almost no cytotoxicity to pancreatic β-cells, and exerts a synergistic effect with Loureirin A (HY-N1505) when binding to human serum albumin. Cochinchinenin C has been widely used in studies of type 2 diabetes, Helicobacter pylori infection, thrombotic diseases, and other conditions .
loading...
    loading...
Cat. No.: HY-108960
CAS No.: 149017-66-3
Research Areas:  

Neurological Disease

PPADS is a P2X receptor (P2X Receptor) antagonist and a reversible competitive antagonist of NAADP receptors, with IC50 values of 68 nM (P2X1) and 214 nM (P2X3), respectively. PPADS alleviates pain-related behaviors in the central and peripheral nervous systems of mice after peripheral neuropathy, inhibits the overproduction of IL-1β, IL-6, iNOS and nNOS, and suppresses the hydrolytic activity of extracellular ATPase. PPADS blocks ATP-mediated inward currents on recombinant rat P2X1 and P2X3 receptors, and inhibits purinergic nerve stimulation-induced contraction of rabbit bladder detrusor muscle. PPADS is applicable to research related to neuropathic pain .
loading...
    loading...
Cat. No.: HY-P5422
Target:  

Calcium Channel

Research Areas:  

Others

Caloxin 3A1 is a biological active peptide. (This peptide belongs to caloxins, the extracellular plasma membrane (PM) Ca2+ pump inhibitors. Caloxin 3A1 inhibits plasma membrane calcium pumps (PMCAs) but not the sarcoplasmic reticulum Ca2+-pump. This peptide does not inhibit formation of the acylphosphate intermediate from ATP.)
loading...
    loading...
Cat. No.: HY-12283R
CAS No.: 156722-18-8
Synonyms: PST 2238 (Standard)
Rostafuroxin (Standard) is the analytical standard of Rostafuroxin. This product is intended for research and analytical applications. Rostafuroxin (PST 2238), a digitoxigenin derivative, is an orally active and potent Na+,K+-ATPase (ATP1A1) antognist. Rostafuroxin binds specifically to the ATP1A1 extracellular domain and blocks respiratory syncytial virus (RSV)-triggered EGFR Tyr845 phosphorylation. Rostafuroxin has antihypertensive and anti-RSV activity .
loading...
    loading...
Cat. No.: HY-143287
CAS No.: 2962812-29-7
Target:  

NTPDase

NTPDase-IN-1 (compound 5a) is a selective NTPDase inhibitor with IC50s of 0.05, 0.23 and 0.54 µM for h-NTPDase-1/-2/-8, respectively. NTPDase-IN-1 non-competitively inhibits h-NTPDase-1/-2 with a Km of 21 µM for h-NTPDase-1. NTPDase-IN-1 can be used in studies of cancer, immunologic disorders as well as bacterial infections .
loading...
    loading...
Cat. No.: HY-P990038
CAS No.: 2682847-53-4
Synonyms: ES002023; ES002

Target:  

NTPDase

Research Areas:  

Neurological Disease

Eurestobart (ES002023) is a recombinant human IgG1 antibody against CD39. Eurestobart restores antitumor immunity by stabilizing the pro-inflammatory extracellular ATP (eATP) and interfering with synthesis of the immunosuppressive adenosine within the tumor microenvironment (TME). Eurestobart is used in the research of locally advanced and metastatic solid tumors .
loading...
    loading...
Cat. No.: HY-137381
CAS No.: 30275-80-0
Synonyms: N6-Benzoyl-cAMP
Target:  

PKA Potassium Channel

Research Areas:  

Metabolic Disease

6-Bnz-cAMP, a derivative of cyclic adenosine monophosphate (cAMP), is a selective PKA activator with inhibitory activity against the bTREK-1 K + channel. 6-Bnz-cAMP does not activate the Epac signaling pathway. 6-Bnz-cAMP inhibits the bTREK-1 K + channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. 6-Bnz-cAMP can be used in studies related to bone tissue repair and regeneration .
loading...
    loading...
Cat. No.: HY-34154R
CAS No.: 619-60-3
Target:  

Reference Standards

Research Areas:  

Others

4-(Dimethylamino)phenol (Standard) is the analytical standard of 4-(Dimethylamino)phenol. This product is intended for research and analytical applications. 4-(Dimethylamino)phenol is a potent cyanide antidote. 4-(Dimethylamino)phenol increases the extracellular lactate dehydrogenase (LDH) without markedly affecting gluconeogenesis. 4-(Dimethylamino)phenol cannot decreases the ATP content until the membrane becomes permeable to LDH. 4-(Dimethylamino)phenol’s toxicity is related to its reaction with glutathione and formation of covalent complexes, leading to impaired cellular function .
loading...
    loading...
Cat. No.: HY-P992446

Target:  

NTPDase

Research Areas:  

Cancer

PUR001 is a monoclonal antibody targeting NTPDase 1 (CD39). PUR001 blocks the hydrolysis of extracellular ATP and ADP into AMP by inhibiting CD39, reduces the production of immunosuppressive adenosine, and increases extracellular ATP concentration to activate anti-tumor immune responses. PUR001 can be used in studies related to solid tumors .
loading...
    loading...
Cat. No.: HY-W017180
CAS No.: 72707-66-5
Synonyms: α-(Bromomethyl)acrylic acid; α-Methylated acrylamide; α-MAA
Target:  

Drug Intermediate

Research Areas:  

Cancer

2-(Bromomethyl) acrylic acid (α-MAA) is a component of Ibt-DOX (HY-181546) .
loading...
    loading...
Cat. No.: HY-L144
1,088 compounds

Normal mitochondrial function is critical for maintaining cellular homeostasis because mitochondria produce ATP and are the major intracellular source of free radicals. Cellular dysfunctions induced by intracellular or extracellular insults converge on mitochondria and induce a sudden increase in permeability on the inner mitochondrial membrane, the so-called mitochondrial membrane permeability transition (MMPT). MMPT is caused by the opening of pores in the inner mitochondrial membrane, matrix swelling, and outer membrane rupture. The MMPT is an endpoint to initiate cell death because the pore opening together with the release of mitochondrial cytochrome c activates the apoptotic pathway of caspases.

The normal operation of mitochondrial function is important for maintaining normal cell death and treatment of mitochondrial diseases. MCE offers a unique collection of 1,088 compounds with identified and potential mitochondrial protective activity. MCE Mitochondrial Protection Compound Library is critical for drug discovery and development.

Cat. No.: HY-184501
CAS No.: 486440-74-8
Research Areas:  

Cancer

UE01 is an orally active, selective small-molecule modulator targeting both ULK1/ERK1/2. UE01 activates hULK1 with an EC50 of 695.30 nM and a KD of 114.3 nM for ULK1; it inhibits hERK1 with an IC50 of 179.90 nM and a KD of 114 nM for ERK1; it shows weak binding to ERK2 with a KD of 2.8 mM. UE01 induces the conformational transition of ULK1 from an inactive to an active state, enhances the phosphorylation of ULK1 Ser317 and mAtg13 Ser355, and reduces the phosphorylation of ULK1 Ser757. UE01 competitively occupies the ATP-binding pocket of ERK1, inhibits ERK1 kinase activity, and reduces the activity of the ERK1/2 signaling pathway. UE01 induces complete autophagy flux and apoptosis, upregulates Atg5, Atg7, LC3-II/LC3-I, Bax, cytochrome C (Cyt c), Cleaved-Caspase 3, Cleaved-PARP1 and E-cadherin, downregulates p62, Bcl-2, MMP-2 and MMP-9, reduces the phosphorylation of Exo70 Ser250, and promotes the proteasome-dependent degradation of Cav-1, thereby inhibiting EMT-related phenotypes and extracellular matrix degradation. UE01 can be used in studies related to triple-negative breast cancer .
loading...
    loading...
  • 1